Recombinant erythropoietin fusion protein - Merck SeronoAlternative Names: FC EPO
Latest Information Update: 08 Apr 2009
At a glance
- Originator Merck Serono
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Anaemia in Switzerland (Parenteral)
- 24 Oct 2007 Phase-I clinical trials in Anaemia in Switzerland (Parenteral)